ArticleThe Journal of clinical investigation1998
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed.
- Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.BMC veterinary research · 2015Trial
- Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.BMC veterinary research · 2015Trial
- Expression of Cytokines, Chmokines and Growth Factors in Patients Undergoing Cataract Surgery with Femtosecond Laser Pretreatment.PloS one · 2015Trial
- A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Trial
- Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma.World journal of gastroenterology · 2007Trial
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- How can we balance risk and benefit of interleukin-18 armored T cell therapies?Experimental biology and medicine (Maywood, N.J.) · 2026Review
- NLRP3 inflammasome in health and disease (Review).International journal of molecular medicine · 2025Review
- Combined delivery of IL12 and an IL18 mutant without IL18BP-binding activity by an adenoviral vector enhances tumor specific immunity.Scientific reports · 2025Article
- Weal and woe of interleukin-18 in the T cell therapy of cancer.Journal for immunotherapy of cancer · 2025Review
- Development of anti-murine IL-18 binding protein antibodies to stimulate IL-18 bioactivity.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Article
- CCL11 released by GSDMD-mediated macrophage pyroptosis regulates angiogenesis after hindlimb ischemia.Cell death discovery · 2024Article
- Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
- Investigation of integrated time nanosecond pulse irreversible electroporation against spontaneous equine melanoma.Frontiers in veterinary science · 2024Article
- The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma.Clinical epigenetics · 2023Article
- Article
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- Article
- Cytokine Imprint in Preeclampsia.Frontiers in immunology · 2021Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antitumor effect and mechanisms activated by murine IL-12 and IL-18, cytokines that induce IFN-gamma production, were studied using engineered SCK murine mammary carcinoma cells. In syngeneic A/J mice, SCK cells expressing mIL-12 or mIL-18 were less tumorigenic and formed tumors more slowly than control cells. Neither SCK.12 nor SCK.18 cells protected significantly against tumorigenesis by distant SCK cells. However, inoculation of the two cell types together synergistically protected 70% of mice from concurrently injected distant SCK cells and 30% of mice from SCK cells established 3 d earlier. Antibody neutralization studies revealed that the antitumor effects of secreted mIL-12 and mIL-18 required IFN-gamma. Interestingly, half the survivors of SCK.12 and/or SCK.18 cells developed protective immunity suggesting that anti-SCK immunity is unlikely to be responsible for protection. Instead, angiogenesis inhibition, assayed by Matrigel implants, appeared to be a property of both SCK.12 and SCK.18 cells and the two cell types together produced significantly greater systemic inhibition of angiogenesis. This suggests that inhibition of tumor angiogenesis is an important part of the systemic antitumor effect produced by mIL-12 and mIL-18.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.